Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

NCT ID: NCT00579566Sponsor: Memorial Sloan Kettering Cancer CenterLast updated: 2025-07-30

Summary

The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue. We will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your samples. We will only use extra tissue left over after all needed testing has been done or remove an additional small amount of tissue if you are having a biopsy. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of sarcoma.

Detailed description

In this protocol, we plan to identify specific markers from biochemical, proteomic, epigenetic and molecular genetic analyses that predict clinical outcome, responsiveness to therapy and might serve as promising therapeutic targets in patients with soft tissue sarcoma.

Arms & interventions

  • OtherSpecimen protocol

    The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.

Outcome measures

Primary

  • establish and maintain a specimen bank and sarcoma cell line resource

    for laboratory-based studies on the causes, prevention, diagnosis and treatment of human soft tissue sarcoma

    Time frame: 2 years

Secondary

  • identify new rational therapeutic targets

    Time frame: 2 years

Eligibility criteria

Sex: AllAge: All agesHealthy volunteers: No
Inclusion Criteria: * All patients with known or suspected sarcoma who will have or have had tissue removed for therapeutic or diagnostic purposes. * Patients will be entered without preference for any particular racial/ethnic group or gender. * Patients may have received prior hormonal therapy, cytotoxic chemotherapy, irradiation, immunotherapy or surgical therapy. * Tissue specimens must be large enough in quantity to allow routine pathologic analysis, with the research laboratory specimen removed from the residual specimen, which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue - 0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or muscle tissue - 30 mg (three 3 x 3 x 3 mm cube Exclusion Criteria: \- None

Study locations (7)

Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up)

Basking Ridge, New Jersey, 07920

Recruiting
Samuel Singer, MD · Contact

Memorial Sloan Kettering Monmouth (Consent and Followup)

Middletown, New Jersey, 07748

Recruiting
Samuel Singer, MD · Contact

Memorial Sloan Kettering Bergen (Consent and Follow up)

Montvale, New Jersey, 07645

Recruiting
Sam Singer, MD · Contact

Memorial Sloan Kettering Commack (Consent and Follow-Up)

Commack, New York, 11725

Recruiting
Samuel Singer, MD · Contact

Memorial Sloan Kettering Westchester (Consent and Followup)

Harrison, New York, 10604

Recruiting
Samuel Singer, MD · Contact

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065

Recruiting
Samuel Singer, M.D. · Contact
Samuel Singer, M.D. · Principal Investigator

Memorial Sloan Kettering Nassau (Consent and Followup)

Rockville Centre, New York, 11553

Recruiting
Sam Singer, MD · Contact
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma | Cancerify